Sanofi Drug Shows Long-Term Safety, Efficacy
Blueprint Medicines, a Sanofi company, announced four-year data from its PIONEER study on the drug AYVAKIT. The results show a sustained benefit and long-term safety profile for patients with indolent systemic mastocytosis, a rare blood disorder.
Indolent systemic mastocytosis (ISM) is a chronic disease caused by the accumulation of abnormal mast cells, affecting roughly 1 in 10,000 people in Europe. In about 95% of cases, the disease is driven by a specific genetic mutation known as KIT D816V, which causes these mast cells to become overactive. Symptoms can be severe and unpredictable, ranging from skin lesions and gastrointestinal issues to brain fog and bone pain. AYVAKIT (avapritinib) is not a traditional chemotherapy but a precision therapy known as a tyrosine kinase inhibitor. It is specifically designed to target and block the activity of the KIT D816V mutation, addressing the underlying cause of the disease rather than just its symptoms. Prior to AYVAKIT's approval, treatment for ISM was primarily supportive, focusing on managing symptoms. This involved a regimen of H1 and H2 antihistamines, mast cell stabilizers, and leukotriene inhibitors to control issues like itching, flushing, and gastrointestinal distress. The U.S. Food and Drug Administration (FDA) approved AYVAKIT for adults with ISM on May 22, 2023, making it the first and only therapy approved to treat this specific condition. This approval represented a significant shift from purely symptomatic management to a disease-modifying treatment for this patient population. The approval was based on the PIONEER trial, a randomized, double-blind, placebo-controlled study. The pivotal part of the trial enrolled 212 patients with moderate-to-severe symptoms that were not adequately controlled by other therapies; 141 patients received AYVAKIT while 71 received a placebo. The long-term data comes from the open-label extension phase of the study, where all participants could receive AYVAKIT. With a median follow-up of more than three years, the drug showed a strong safety profile, with only a 3% discontinuation rate due to treatment-related adverse events. The most common adverse reactions reported in patients taking AYVAKIT were generally mild to moderate. These included eye edema, dizziness, peripheral edema (swelling in arms and legs), and flushing.
